GAVI (Gavi, the Vaccine Alliance)

GAVI (Gavi, the Vaccine Alliance) is a public–private partnership formed in 2000 to increase access to immunisation in low-income countries. It brings together Bill & Melinda Gates Foundation, World Health Organization, United Nations Children's Fund, World Bank, national Ministry of Healths, vaccine manufacturers such as GlaxoSmithKline, Pfizer, Sanofi, Merck & Co., and civil society organisations like Red Cross societies to coordinate financing, procurement, and delivery of vaccines. Gavi has played a central role in introducing new vaccines including pneumococcal, rotavirus, human papillomavirus, and COVID-19 vaccines in alliance with initiatives such as COVAX.

History

Gavi was launched at the World Economic Forum meeting in Davos and formally created following a 1999 proposal by World Bank officials and philanthropists including Ted Turner and James Wolfensohn. Its early governance involved partnerships with World Health Organization, UNICEF, and the Bill & Melinda Gates Foundation to address shortfalls identified by analyses from Global Fund to Fight AIDS, Tuberculosis and Malaria and reports from Save the Children and Médecins Sans Frontières. Major milestones include the 2006 introduction of the Hib vaccine and pneumococcal conjugate vaccine rollouts supported by GAVI Alliance fundraising pledges from donor states such as United Kingdom, United States, Norway, France, and Germany and commitments from private donors like Carlos Slim. Gavi's financing architecture evolved with instruments inspired by the International Finance Facility for Immunisation and the launch of Advance Market Commitment mechanisms negotiated with GAVI's AMC partners and vaccine manufacturers including Novartis and AstraZeneca.

Governance and funding

Gavi's governance structure includes a Board composed of representatives from donor nations such as Japan, Canada, Italy, and Sweden; implementing countries from India, Nigeria, Ethiopia, and Brazil; private sector partners like GlaxoSmithKline and Pfizer; and global institutions including WHO, UNICEF, and the World Bank. Financial support has come from sovereign donors (e.g., United Kingdom, United States) and philanthropic entities including the Bill & Melinda Gates Foundation and Wellcome Trust. Innovative financing tools include vaccine bonds and market-shaping instruments similar to those used by European Investment Bank programs, while partnerships with entities such as Global Alliance for TB Drug Development and PATH inform procurement strategies. Gavi's replenishment conferences have attracted participation from heads of state including Barack Obama, Angela Merkel, Emmanuel Macron, and Justin Trudeau and multilateral lenders like Asian Development Bank and African Development Bank.

Vaccine programs and impact

Gavi has supported the introduction of vaccines against measles, diphtheria, tetanus, pertussis, hepatitis B, rotavirus, HPV, and pneumococcal disease. Impact assessments by institutions such as Institute for Health Metrics and Evaluation, Lancet research teams, and World Health Organization evaluations attribute reductions in under‑5 mortality and outbreaks contained in countries like Pakistan, Bangladesh, Kenya, Ghana, and Rwanda to Gavi-supported campaigns. Programs have used cold chain technologies adapted from UNICEF logistics, surveillance coordination with CDC, and data systems interoperable with DHIS2 platforms. During the 2014 West African Ebola epidemic and the COVID-19 pandemic, Gavi participated in emergency immunisation initiatives alongside CEPI and Gates Foundation funding to accelerate access to novel vaccines manufactured by Moderna and AstraZeneca partners.

Partnerships and global role

Gavi operates as a hub connecting governments (e.g., India, China, South Africa), multilateral agencies (WHO, UNICEF, World Bank), philanthropic actors (Bill & Melinda Gates Foundation), industry (Sanofi Pasteur, Merck Sharp & Dohme), and NGOs (Médecins Sans Frontières, Save the Children, International Federation of Red Cross and Red Crescent Societies). It collaborates with regulatory bodies such as European Medicines Agency and U.S. Food and Drug Administration for vaccine approvals and quality assurance, and with procurement platforms used by Pan American Health Organization. Gavi's market-shaping role influences production strategies in manufacturers across Belgium, India (e.g., Serum Institute of India), Germany, and United States, and informs regional immunisation policies discussed at forums like the World Health Assembly and G20 meetings. Alliances with research institutions including University of Oxford, Johns Hopkins University, Harvard University, and Imperial College London support vaccine impact modelling and health systems strengthening.

Criticism and controversies

Gavi has faced critiques from organisations such as Médecins Sans Frontières and academics from London School of Hygiene & Tropical Medicine and University College London over governance transparency, influence of private donors like the Bill & Melinda Gates Foundation, and procurement practices that may advantage large multinational manufacturers including GlaxoSmithKline and Pfizer. Debates have arisen around the Advance Market Commitment mechanism and its fiscal implications raised by analysts at International Monetary Fund and Overseas Development Institute. Questions about vaccine equity emerged during allocations in the COVID-19 pandemic with scrutiny from members of European Parliament and human rights advocates. Operational challenges in fragile contexts such as South Sudan, Democratic Republic of the Congo, and Yemen highlighted logistical constraints noted by Oxfam and the Norwegian Refugee Council, prompting calls for reforms in accountability and engagement with civil society actors.

Category:Global health organizations